This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

XOMA's Management Presents At Morgan Stanley Global Healthcare Conference (Transcript)

XOMA Corporation (XOMA)

Morgan Stanley Global Healthcare Conference

September 12, 2012 10:20 a.m. ET


Paul Rubin - Senior Vice President, Research and Development and Chief Medical Officer

Fred Kurland - Vice President-Finance and Chief Financial Officer


Yigal Nochomovitz - Morgan Stanley

Good morning everyone. Welcome to the XOMA session. My name is Yigal Nochomovitz, I am one of the biotech analysts at Morgan Stanley. And so just a few orders of business before we get started. All relevant research disclosures from Morgan Stanley can be found on our website or on our publicly printed notes. And secondarily, this is meant to be an absolutely open question-and-answer session, so feel free to raise your hand and interrupt at any point. We have microphones circulating around the room.

So welcome, Paul Rubin, CMO of XOMA, and Fred Kurland, CFO. Welcome to the session. Maybe we could start off, Paul, just give us a little bit of an overview of XOMA. What are the key priorities of the company at this point? Just flush out the story for those that are not familiar with the company.

Paul Rubin

Sure. First thank you for having us here. XOMA is a discovery based biotechnology company that, not surprisingly people know, has been around for quite a while. But during the time it’s been around it’s developed I think a very proprietary method which to discover monoclonal antibodies. It probably has some of the best libraries in the world plus our ability to interrogate receptors, especially through use of allosteric modulation I think is very unique. And at the day we should be able to determine potential monoclonals that could be differentiated from many other companies in the world.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,678.23 -40.31 -0.23%
S&P 500 2,056.15 -4.90 -0.24%
NASDAQ 4,863.3620 -13.1570 -0.27%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs